Adenosquamous Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: ADN009 MIFTS: 46	Adenosquamous Carcinoma Categories: Cancer diseases, Endocrine diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Adenosquamous Carcinoma

MalaCards integrated aliases for Adenosquamous Carcinoma:

Name: Adenosquamous Carcinoma ¹¹ ¹⁴ ¹⁶ ⁷¹ ⁷⁵

Mixed Adenocarcinoma and Squamous Carcinoma ¹¹

Adenosquamous Cell Carcinoma ¹¹

Carcinoma, Adenosquamous ⁴³

Carcinoma Adenosquamous ⁵³

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Endocrine diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:4830

MeSH ⁴³ D018196

NCIt ⁴⁹ C3727

SNOMED-CT ⁶⁸ 403902008

EFO ¹⁶ EFO_1000073

UMLS ⁷¹ C0206623

Sources

Summaries for Adenosquamous Carcinoma

Disease Ontology: ¹¹ A squamous cell carcinoma that contains squamous cells and gland-like cells.

MalaCards based summary: Adenosquamous Carcinoma, also known as mixed adenocarcinoma and squamous carcinoma, is related to adenosquamous gallbladder carcinoma and esophageal adenosquamous carcinoma. An important gene associated with Adenosquamous Carcinoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are COPI-independent Golgi-to-ER retrograde traffic and Keratinization. The drugs Topotecan and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include pancreas, cervix and lung, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia: ⁷⁵ Adenosquamous carcinoma is a type of cancer that contains two types of cells: squamous cells (thin, flat... more...

Sources

Related Diseases for Adenosquamous Carcinoma

Diseases related to Adenosquamous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 646)

#	Related Disease	Score	Top Affiliating Genes
1	adenosquamous gallbladder carcinoma	32.7	KRT7 KRT5 KRT19
2	esophageal adenosquamous carcinoma	32.6	KRT7 KRT5 CEACAM5
3	vaginal cancer	32.2	PGR KRT7 EGFR
4	adenosquamous bile duct carcinoma	32.2	KRT7 KRT19 CEACAM5
5	breast metaplastic carcinoma	31.1	PGR KRT7 KRT5
6	gallbladder adenocarcinoma	31.0	MUC5AC MUC1 KRT7 CHGA CEACAM5
7	adenoid squamous cell carcinoma	31.0	KRT8 KRT7 KRT5 KRT19 CEACAM5
8	squamous cell carcinoma	30.9	TP63 PTHLH NKX2-1 MUC1 KRT7 KRT19
9	cervix carcinoma	30.9	PGR KRT7 EGFR CEACAM5
10	lung squamous cell carcinoma	30.8	PTHLH KRT19 EGFR CEACAM5
11	adenocarcinoma	30.8	NKX2-1 MUC5AC MUC4 MUC1 KRT7 KRT20
12	rectum cancer	30.8	KRT20 EGFR CEACAM7 CEACAM5
13	intrahepatic cholangiocarcinoma	30.8	MUC4 KRT7 KRT19 EGFR CEACAM5
14	cervical squamous cell carcinoma	30.7	TP63 KRT8 EGFR CEACAM5
15	cervical adenocarcinoma	30.7	PGR MUC5AC KRT8 KRT7 KRT20 CEACAM7
16	endometrial adenocarcinoma	30.7	PGR KRT7 EGFR
17	endometrial cancer	30.7	PGR MUC1 KRT7 KRT20 KDR EGFR
18	lip and oral cavity cancer	30.7	KRT19 IVL EGFR
19	rectal benign neoplasm	30.6	KRT7 KRT20 EGFR CEACAM5
20	gastric adenocarcinoma	30.6	MUC4 KRT20 CHGA CEACAM5
21	carcinosarcoma	30.6	PGR MUC1 KRT7 EGFR
22	mucoepidermoid carcinoma	30.6	TP63 MUC5AC MUC4 MUC1 KRT8 KRT7
23	appendix adenocarcinoma	30.6	KRT7 KRT20 CHGA CEACAM5
24	bile duct cysts	30.6	KRT7 KRT19 CEACAM5
25	klatskin's tumor	30.6	KRT7 KRT19 CEACAM5
26	cholangiocarcinoma	30.5	MUC5AC MUC4 MUC1 KRT8 KRT7 KRT20
27	ampulla of vater cancer	30.5	MUC5AC MUC1 KRT7 KRT20 EGFR CEACAM5
28	small cell cancer of the lung	30.5	NKX2-1 KRT7 KRT20 EGFR CHGA CEACAM5
29	teratoma	30.5	NKX2-1 MUC1 KRT7 KRT20 CHGA CEACAM5
30	keratinizing squamous cell carcinoma	30.5	NKX2-1 KRT7 KRT5 EGFR CEACAM5
31	endocervical adenocarcinoma	30.5	PGR KRT7 CEACAM5
32	papillary adenocarcinoma	30.5	NKX2-1 MUC1 KRT7 KRT5 CEACAM5
33	gallbladder cancer	30.5	MUC5AC MUC1 KRT8 KRT7 KRT20 KRT19
34	cystic teratoma	30.5	NKX2-1 MUC1 KRT7 KRT20 CHGA CEACAM5
35	keratoacanthoma	30.5	TP63 KRT8 KRT19 IVL EGFR
36	necrotizing sialometaplasia	30.4	KRT7 KRT5
37	breast fibroadenoma	30.4	PGR KRT8 KRT5 EGFR
38	skin benign neoplasm	30.4	TP63 KRT7 KRT5 KRT20
39	mucoepidermoid esophageal carcinoma	30.4	KRT5 CEACAM5
40	adenosquamous breast carcinoma	30.4	PGR KRT5
41	papilloma	30.4	TP63 KRT8 KRT7 KRT5 KRT20 IVL
42	gastric squamous cell carcinoma	30.4	KRT7 KRT5
43	anal canal carcinoma	30.4	KRT7 KRT5 KRT20 CEACAM5
44	benign teratoma	30.4	NKX2-1 KRT7 KRT5 KRT20 CHGA CEACAM5
45	colorectal adenocarcinoma	30.4	KRT7 KRT20 EGFR CEACAM5
46	lung benign neoplasm	30.4	NKX2-1 KRT7 KRT20 EGFR CHGA
47	bronchus cancer	30.4	KRT7 EGFR CEACAM5
48	adenoma	30.4	MUC5AC MUC1 KRT7 KRT20 KRT19 CHGA
49	small cell carcinoma	30.4	NKX2-1 KRT7 KRT5 KRT20 EGFR CHGA
50	intestinal obstruction	30.4	KRT7 KRT20 CEACAM5

Graphical network of the top 20 diseases related to Adenosquamous Carcinoma:

Sources

Symptoms & Phenotypes for Adenosquamous Carcinoma

MGI Mouse Phenotypes related to Adenosquamous Carcinoma:

⁴⁵ (show all 14)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.37	CEACAM5 CEACAM7 CHGA EGFR KDR KRT7
2	growth/size/body region	MP:0005378	10.32	CEACAM5 CEACAM7 CHGA EGFR IVL KDR
3	normal	MP:0002873	10.26	CEACAM7 EGFR IVL KDR KRT19 MUC1
4	neoplasm	MP:0002006	10.24	CEACAM5 EGFR KRT19 MUC1 MUC4 NKX2-1
5	digestive/alimentary	MP:0005381	10.21	CEACAM5 EGFR KRT19 KRT5 KRT8 MUC1
6	no phenotypic analysis	MP:0003012	10.16	CHGA EGFR KDR KRT19 MUC1 NKX2-1
7	endocrine/exocrine gland	MP:0005379	10.16	CEACAM5 CHGA EGFR KRT19 MUC1 NKX2-1
8	cardiovascular system	MP:0005385	10.15	CEACAM5 CHGA EGFR IVL KDR KRT19
9	immune system	MP:0005387	10.13	CEACAM5 CEACAM7 EGFR KDR KRT19 KRT5
10	craniofacial	MP:0005382	9.95	EGFR KDR KRT19 KRT5 PDGFRA PTHLH
11	respiratory system	MP:0005388	9.86	EGFR KDR KRT19 MUC4 NKX2-1 PDGFRA
12	reproductive system	MP:0005389	9.85	CHGA EGFR IVL KRT19 KRT8 NKX2-1
13	mortality/aging	MP:0010768	9.8	CEACAM5 CEACAM7 CHGA EGFR KDR KRT19
14	integument	MP:0010771	9.32	CEACAM7 EGFR KDR KRT19 KRT5 MUC1

Sources

Drugs & Therapeutics for Adenosquamous Carcinoma

Drugs for Adenosquamous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 120)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Topotecan

Approved, Investigational

Phase 3

123948-87-8, 119413-54-6

60699 60700

Gemcitabine

Approved

Phase 3

95058-81-4, 122111-03-9

60750

Doxorubicin

Approved, Investigational

Phase 3

23214-92-8

31703

Vinorelbine

Approved, Investigational

Phase 3

71486-22-1

44424639 60780

Ipilimumab

Approved

Phase 2, Phase 3

477202-00-9

Pembrolizumab

Approved

Phase 2, Phase 3

1374853-91-4

254741536

Oxaliplatin

Approved, Investigational

Phase 3

61825-94-3

43805 11947679 6857599

Cisplatin

Approved

Phase 3

15663-27-1

2767 5702198 441203

Paclitaxel

Approved, Vet_approved

Phase 3

33069-62-4

36314

Carboplatin

Approved

Phase 3

41575-94-4

10339178 38904

Erlotinib

Approved, Investigational

Phase 3

183319-69-9, 183321-74-6

176870

Tirapazamine

Investigational

Phase 3

27314-97-2

135413511

Antiviral Agents

Phase 3

Antimetabolites

Phase 3

Epoetin Alfa

Phase 3

Hematinics

Phase 3

Chrysarobin

Phase 3

Liposomal doxorubicin

Phase 3

Vitamins

Phase 3

Hormones

Phase 3

Trace Elements

Phase 3

topoisomerase I inhibitors

Phase 3

Antidotes

Phase 3

Calcium, Dietary

Phase 3

Micronutrients

Phase 3

Protective Agents

Phase 3

Albumin-Bound Paclitaxel

Phase 3

Immunoglobulins

Phase 3

Antimitotic Agents

Phase 3

Tubulin Modulators

Phase 3

Antibodies, Monoclonal

Phase 3

Antibodies

Phase 3

Mitogens

Phase 3

Protein Kinase Inhibitors

Phase 3

Insulin, Globin Zinc

Phase 3

Insulin

Phase 3

Calcium

Nutraceutical

Phase 3

7440-70-2

271

Atezolizumab

Approved, Investigational

Phase 2

1380723-44-3

Medroxyprogesterone acetate

Approved, Investigational

Phase 2

520-85-4, 71-58-9

6279 10631

Capecitabine

Approved, Investigational

Phase 2

154361-50-9

60953

Sunitinib

Approved, Investigational

Phase 2

557795-19-4

5329102

Thalidomide

Approved, Investigational, Withdrawn

Phase 2

50-35-1

5426

Metformin

Approved

Phase 2

1115-70-4, 657-24-9

4091

Olaparib

Approved

Phase 2

763113-22-0

23725625

Coenzyme M

Approved, Investigational

Phase 2

3375-50-6

598 23662354

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

135329020

Nivolumab

Approved

Phase 2

946414-94-4

Lenograstim

Approved, Investigational

Phase 2

135968-09-1

Sirolimus

Approved, Investigational

Phase 2

53123-88-9

5284616 6436030

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Interventional clinical trials:

(show top 50) (show all 79)

#	Name	Status	NCT ID	Phase	Drugs
1	A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865) Versus the Non-platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix	Completed	NCT00803062	Phase 3	Cisplatin;Paclitaxel;Topotecan Hydrochloride
2	Phase III Trial to Evaluate the Efficacy of Maintaining Hemoglobin Levels Above 120 g/l With Erythropoietin Versus Above 100 g/l Without Erythropoietin in Anemic Patients Receiving Concurrent Radiation and Cisplatin for Cervical Cancer	Completed	NCT00017004	Phase 3	Cisplatin
3	A Randomized Phase III Trial Of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin In Stage IVB, Recurrent Or Persistent Carcinoma of the Cervix	Completed	NCT00064077	Phase 3	Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
4	A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma	Completed	NCT00006011	Phase 3	Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
5	A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial	Completed	NCT01414608	Phase 3	Carboplatin;Cisplatin;Paclitaxel
6	A Phase III Randomized Study of Pretherapeutic Para-aortic Lymphadenectomy in Women With Locally Advanced Cervical Cancer Dispositioned to Definitive Chemoradiotherapy	Completed	NCT01365156	Phase 3
7	A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer	Recruiting	NCT04929041	Phase 2, Phase 3	Carboplatin;Nab-paclitaxel;Paclitaxel;Pemetrexed
8	A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer	Recruiting	NCT04340141	Phase 3	Oxaliplatin;Irinotecan Hydrochloride;Leucovorin Calcium;Fluorouracil
9	A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer	Active, not recruiting	NCT02466971	Phase 3	Cisplatin;Triapine
10	Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)	Active, not recruiting	NCT01101451	Phase 3	Cisplatin
11	PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer.	Not yet recruiting	NCT05581121	Phase 3
12	Randomized Phase III Trial Evaluating the Impact of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer	Terminated	NCT01363466	Phase 3
13	A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIIB and IVA Cervical Carcinoma Limited to the Pelvis	Terminated	NCT00262821	Phase 3	cisplatin;tirapazamine
14	Randomized, Open Label, Phase 3 Trial Of Erlotinib Alone Or In Combination With CP-751,871 In Patients With Advanced Non Small Cell Lung Cancer Of Non Adenocarcinoma Histology	Terminated	NCT00673049	Phase 3	CP 751,871 (Figitumumab);Erlotinib
15	Randomized, Open Label, Phase III Trial Of CP- 751,871 In Combination With Paclitaxel And Carboplatin Versus Paclitaxel And Carboplatin In Patients With Non Small Cell Lung Cancer	Terminated	NCT00596830	Phase 3	CP-751,871 (Figitumumab);Carboplatin;Paclitaxel
16	Efficacy and Safety of Nimotuzumab Combined With Radiotherapy and Concurrently Cisplatin in Patients With Stage IIB-IVA Cervical Squamous Cell Carcinoma	Unknown status	NCT03469531	Phase 2	Nimotuzumab;Cisplatin
17	A PHASE II STUDY OF BEVACIZUMAB IN COMBINATION WITH DEFINITIVE RADIOTHERAPY AND CISPLATIN CHEMOTHERAPY IN UNTREATED PATIENTS WITH LOCALLY ADVANCED CERVICAL CARCINOMA	Completed	NCT00369122	Phase 2	Cisplatin
18	A Phase II Evaluation of Gemcitabine (Gemzar®, LY188011) in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT00820898	Phase 2	Gemcitabine Hydrochloride
19	A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer	Completed	NCT01005329	Phase 2	Carboplatin;Cisplatin;Paclitaxel
20	A Phase II Pilot Investigation Of The Relationship Of Short Term Depo-Provera (Medroxyprogesterone Acetate) Exposure To The Morphologic , Biochemical, And Molecular Changes In Primary Endometroid Adenocarcinoma of the Uterine Corpus	Completed	NCT00064025	Phase 2	Medroxyprogesterone
21	A Phase II Evaluation Of Capecitabine (NSC #712807) In The Treatment Of Persistent Or Recurrent Non-Squamous Cell Carcinoma Of The Cervix	Completed	NCT00039442	Phase 2	Capecitabine
22	A Phase II Evaluation of AZD6244 (NSC #748727) in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT01011933	Phase 2	Selumetinib
23	A Phase II Evaluation of Cediranib (Recentin; AZD2171, IND#72740, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT01132820	Phase 2	Cediranib Maleate
24	A Phase II Study of Oxaliplatin in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Cervical Cancer	Completed	NCT00057863	Phase 2	Paclitaxel;Oxaliplatin
25	Prospective Evaluation of Pelvic Exenteration in Patients With Recurrent Cervical Cancer	Completed	NCT00217633	Phase 2
26	A Phase II Evaluation of ABI-007 in the Treatment of Persistent or Recurrent Squamous or Nonsquamous Cell Carcinoma of the Cervix	Completed	NCT00309959	Phase 2	Paclitaxel Albumin-Stabilized Nanoparticle Formulation
27	A Phase II Randomized Study of OSI-774 (Erlotinib) (NSC #718781) With or Without Carboplatin/Paclitaxel in Patients With Previously Untreated Adenocarcinoma of the Lung Who Never Smoked or Were Former Light Smokers	Completed	NCT00126581	Phase 2	Carboplatin;Erlotinib;Erlotinib Hydrochloride;Paclitaxel
28	A Phase II Study of Temsirolimus (NSC 683864), an mTOR Inhibitor, in Patients With Recurrent, Unresectable, Locally Advanced or Metastatic Carcinoma of the Cervix	Completed	NCT01026792	Phase 2	Temsirolimus
29	A Phase II Evaluation of ADXS11-001 (NSC 752718) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix	Completed	NCT01266460	Phase 2
30	A Phase II Evaluation of ABT-888 (NCI Supplied Agent: ABT-888, NSC #737664), Topotecan (NSC # 609699) and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Squamous or Non-squamous Cell Carcinoma of the Cervix	Completed	NCT01266447	Phase 2	Topotecan Hydrochloride;Veliparib
31	A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)	Completed	NCT01267253	Phase 2	Brivanib Alaninate
32	A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer	Completed	NCT02921269	Phase 2	Atezolizumab
33	A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium	Completed	NCT01210222	Phase 2
34	A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer	Completed	NCT01307631	Phase 2	Akt Inhibitor MK2206
35	Phase II Clinical Trial of Bryostatin-1, NSC 339555, and Cisplatin in Patients With Recurrent and/or Advanced Inoperable Squamous Cell, Adeno or Adenosquamous Cell Carcinoma of the Cervix	Completed	NCT00005965	Phase 2	bryostatin 1;cisplatin
36	Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage	Completed	NCT00416455	Phase 1, Phase 2	ferumoxtran-10
37	A Phase II Study of Sunitinib (SU11248; NSC 736511) an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients With Unresectable, Locally Advanced or Metastatic Cervical Carcinoma	Completed	NCT00389974	Phase 2	sunitinib malate
38	A Phase II Study of CCI-779 in Patients With Metastatic and/or Locally Advanced Recurrent Endometrial Cancer	Completed	NCT00072176	Phase 2	temsirolimus
39	A Phase II Evaluation of Thalidomide (NSC #66847, IND 48832) in the Treatment of Recurrent of Persistent Endometrial Carcinoma	Completed	NCT00025467	Phase 2	thalidomide
40	PHASE 1-2 STUDY EVALUATING HIGH DOSE ADXS11-001 (1 x 10^10 CFU) TREATMENT IN WOMEN WITH HPV+ CARCINOMA OF THE CERVIX	Completed	NCT02164461	Phase 1, Phase 2
41	The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial	Completed	NCT02394652	Phase 2	Metformin;Cisplatin;FAZA
42	APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation	Recruiting	NCT04858334	Phase 2	Olaparib;Placebo Administration
43	A Phase II Trial of the Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)	Recruiting	NCT04896073	Phase 2	Minnelide
44	Efficacy and Safety of Pemigatinib in Subjects With Advanced Metastatic or Surgically Unresectable Adenosquamous Carcinoma of the Pancreas (ASCP) Who Have Progressed On Previous Therapy	Recruiting	NCT05216120	Phase 2	Pemigatinib 4.5 MG
45	A Phase II Study Using Autologous Young Tumor-Infiltrating Lymphocytes Derived From Patients With Non-Small Cell Lung Cancer Following Non-Myeloablative Lymphocyte Depleting Preparative Regimen	Recruiting	NCT02133196	Phase 2	Aldesleukin;Fludarabine;Cyclophosphamide
46	An Open-label, Multicenter , Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 ( Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection) Combination Therapy or Monotherapy in Patients With Locally Advanced, Unresectable or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)	Recruiting	NCT05221658	Phase 2	HLX07+HLX10+ Cisplatin+5-FU;HLX07
47	A Safety Lead in Single Arm Phase II Study for Image Guided Ultrafractionated Radiation Therapy for Treatment of Metastatic Cervical Cancer	Recruiting	NCT05021237	Phase 2
48	A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer	Active, not recruiting	NCT01935934	Phase 2	Cabozantinib S-malate
49	A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer	Active, not recruiting	NCT02257528	Phase 2
50	A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer	Active, not recruiting	NCT00977574	Phase 2	Carboplatin;Ixabepilone;Paclitaxel;Temsirolimus

Search NIH Clinical Center for Adenosquamous Carcinoma

Cochrane evidence based reviews: carcinoma, adenosquamous

Sources

Genetic Tests for Adenosquamous Carcinoma

Sources

Anatomical Context for Adenosquamous Carcinoma

Organs/tissues related to Adenosquamous Carcinoma:

MalaCards : Pancreas, Cervix, Lung, Lymph Node, T Cells, Colon, Breast

Sources

Publications for Adenosquamous Carcinoma

Articles related to Adenosquamous Carcinoma:

(show top 50) (show all 2269)

#	Title	Authors	PMID	Year
1	Reclassifying bronchial-pulmonary carcinoma: differentiating histological type in biopsies by immunohistochemistry. ⁵³ ⁶²	Carvalho L	19859629	2009
2	Large cell carcinoma of the lung: an endangered species? ⁵³ ⁶²	Pardo J...Lozano MD	19444077	2009
3	Interferon-alpha conditioned sensitivity to an anti-epidermal growth factor receptor monoclonal antibody in a human lung cancer cell line with intermediate expression of the receptor. ⁵³ ⁶²	Diaz A...Montero E	19514842	2009
4	Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma. ⁵³ ⁶²	Longatto-Filho A...Reis RM	19563658	2009
5	Adenosquamous carcinoma: a report of nine cases with p63 and cytokeratin 5/6 staining. ⁵³ ⁶²	Ko CJ...McNiff JM	19278431	2009
6	Mucoepidermoid carcinoma of the lung, response to EGFR inhibitors, EGFR and K-RAS mutations, and differential diagnosis. ⁵³ ⁶²	Rossi G...Tamberi S	18992960	2009
7	Adenosquamous carcinoma of the pancreas associated with humoral hypercalcemia of malignancy (HHM). ⁵³ ⁶²	Kobayashi N...Inayama Y	18836809	2008
8	Cyclooxygenase-2 and epidermal growth factor receptor expressions in different histological subtypes of cervical carcinomas. ⁵³ ⁶²	Baltazar F...Schmitt FC	17581404	2007
9	Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung. ⁵³ ⁶²	Kang SM...Chang J	17186532	2007
10	Mucinous expression in benign and neoplastic glandular lesions of the uterine cervix. ⁵³ ⁶²	Baker AC...Chhieng D	17090193	2006
11	The correlation between TTF-1 immunoreactivity and the occurrence of lymph node metastases in patients with lung cancer. ⁵³ ⁶²	Altaner S...Kutlu K	17036524	2006
12	Mutations of epidermal growth factor receptor and K-ras genes in adenosquamous carcinoma of the lung. ⁵³ ⁶²	Toyooka S...Shimizu N	16187277	2006
13	Paraneoplastic hypercalcemia with adenosquamous carcinoma of the colon. ⁵³ ⁶²	Fujita T...Komatsubara S	15864702	2005
14	Unique characteristics of rectal carcinoma cell lines derived from invasive carcinomas in ulcerative colitis patients. ⁵³ ⁶²	Yamashita K...Okayasu I	15016319	2004
15	Prospective evaluation of squamous cell carcinoma and carcinoembryonic antigen as prognostic factors in patients with cervical cancer. ⁵³ ⁶²	Molina R...Iglesias J	14610320	2003
16	Colliding primary lung cancers of adenosquamous carcinoma and large cell neuroendocrine carcinoma. ⁵³ ⁶²	Yazawa T...Kitamura H	12558872	2003
17	Neuroendocrine marker expression in cervical carcinomas of non-small cell type. ⁵³ ⁶²	Chavez-Blanco A...Duenas-Gonzalez A	12352185	2002
18	Primary adenosquamous carcinoma of the liver which produces granulocyte-colony-stimulating factor and parathyroid hormone related protein: association with leukocytosis and hypercalcemia. ⁵³ ⁶²	Hayashi T...Yamazaki K	11506305	2001
19	Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. ⁵³ ⁶²	Wang TY...Crum CP	11381365	2001
20	Clinical value of tumor markers for early detection of recurrence in patients with cervical adenocarcinoma and adenosquamous carcinoma. ⁵³ ⁶²	Tabata T...Hasumi K	11006578	2000
21	EGF-dependent and independent programmed cell death pathways in NCI-H596 nonsmall cell lung cancer cells. ⁵³ ⁶²	Lei W...Levitt ML	9588219	1998
22	Different angiogenic pathways in human cervical cancers. ⁵³ ⁶²	Tokumo K...Kudo T	9454658	1998
23	Surfactant protein gene expression in metastatic and micrometastatic pulmonary adenocarcinomas and other non-small cell lung carcinomas: detection by reverse transcriptase-polymerase chain reaction. ⁵³ ⁶²	Betz C...Muller-Hermelink HK	7671236	1995
24	Epidermal growth factor receptor (EGF-R) and transforming growth factor alpha (TGFA) expression in different endometrial cancers. ⁵³ ⁶²	Jasonni VM...Flamigni C	7654016	1995
25	Altered expression of nm23-H1 and c-erbB-2 proteins have prognostic significance in adenocarcinoma but not in squamous cell carcinoma of the uterine cervix. ⁵³ ⁶²	Mandai M...Fukumoto M	7736397	1995
26	Hypercalcaemia in a patient with fatal adenosquamous carcinoma of the colon. ⁵³ ⁶²	Links M...Diamond T	8107631	1994
27	Cathepsin-D expression in cervical carcinoma and its prognostic significance. ⁵³ ⁶²	Mitchell KM...Smith D	8322451	1993
28	Immunocytologic diagnosis of small-cell lung cancer in imprint smears. ⁵³ ⁶²	Tome Y...Shimosato Y	1656682	1991
29	[A parathyroid hormone related protein (PTHrP) implicated in hypercalcemia associated with malignancy: research of the PTHrP for novel hormonal tumor marker]. ⁵³ ⁶²	Wada C...Ohtani H	2348564	1990
30	Compressive optic neuropathy caused by sinonasal adenosquamous carcinoma with orbital extension: A case report. ⁶²	Taylor K...Tsai J	36111279	2022
31	Single-cell RNA-sequencing dissects cellular heterogeneity and identifies two tumor-suppressing immune cell subclusters in HPV-related cervical adenosquamous carcinoma. ⁶²	Li X...Liu C	36000446	2022
32	Differences between complex epithelial neoplasms of the ovary and high-grade serous ovarian cancer: a retrospective observational cohort study. ⁶²	Li X...Yang M	36456989	2022
33	Correction to: Clinicopathological characteristics and prognosis of resectable lung adenosquamous carcinoma: a population-based study of the SEER database. ⁶²		36125310	2022
34	Efficacy of chemotherapy for patients with metastatic or recurrent pancreatic adenosquamous carcinoma: A multicenter retrospective analysis. ⁶²	Yoshida Y...Furuse J	36150984	2022
35	Clinical outcomes after positron emission tomography/computed tomography-based image-guided brachytherapy for cervical cancer. ⁶²	Kim N...Cho YS	35366364	2022
36	Histological patterns, subtypes and aspects of prostate cancer: different aspects, different outcomes. ⁶²	Wasinger G...Comperat E	36081403	2022
37	Long-term treatment outcomes/toxicities of definite chemoradiotherapy (intensity-modulated radiation therapy) for early-stage "bulky" cervical cancer and survival impact of histological subtype. ⁶²	Hsieh HY...Wang L	36379808	2022
38	The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry. ⁶²	Satake T...Kawai A	36161533	2022
39	Adenosquamous Carcinoma of Extrahepatic Bile Duct in Primary Sclerosing Cholangitis. ⁶²	Chiang TH...Desai CS	36028730	2022
40	Progression of a persisting mesenchymal hamartoma to intrahepatic cholangiocarcinoma 24 years after the initial diagnosis: A case report. ⁶²	Gang S...Suh KS	35995570	2022
41	Primary lung carcinoma in children and adolescents: An analysis of the European Cooperative Study Group on Paediatric Rare Tumours (EXPeRT). ⁶²	Abele M...Virgone C	36087394	2022
42	Research advances and treatment perspectives of pancreatic adenosquamous carcinoma. ⁶²	Zhang W...Ding J	36316580	2022
43	Development of an adenosquamous carcinoma histo pathology-selective lung metastasis model. ⁶²	Lahdeniemi IAK...Verschuren EW	36355420	2022
44	Peritoneal carcinomatosis after minimally invasive surgery versus open radical hysterectomy: systematic review and meta-analysis. ⁶²	Hoegl J...Pareja R	36351746	2022
45	Lacrimal sac ciliated HPV16 positive, adenosquamous carcinoma-A case report of a unique histological variant at this site and a review of the literature. ⁶²	Mudhar HS...Salvi SM	36398700	2022
46	Delayed local recurrence of pancreatic adenosquamous cell carcinoma after curative surgery: A case report. ⁶²	Watanabe A...Nakahara M	36257141	2022
47	Pancreatic Adenosquamous Carcinoma: Experience Within an Integrated Health Care System. ⁶²	Kwak HV...Chang CK	36336674	2022
48	Molecular and expressional characterization of tumor heterogeneity in pulmonary carcinosarcoma. ⁶²	Ohtaki Y...Shirabe K	35848137	2022
49	Adenosquamous carcinoma of the pancreas: two case reports and review of the literature. ⁶²	Paramythiotis D...Michalopoulos A	36309754	2022
50	Clinicopathological characteristics and prognosis of resectable lung adenosquamous carcinoma: a population-based study of the SEER database. ⁶²	Wang T...Liu L	35726160	2022

Sources

Genes for Adenosquamous Carcinoma

Genes related to Adenosquamous Carcinoma (0 elite genes):

(show all 31)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	EGFR	Epidermal Growth Factor Receptor	Protein Coding	22.27	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17186532 19563658 7528164 (more) 8459036 7654016 17581404 18992960 17069674 19514842 17238183 9588219 16187277
2	KRT7	Keratin 7	Protein Coding	21.29	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19278431 19444077 19859629
3	TP63	Tumor Protein P63	Protein Coding	20.49	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19278431 12210069 11381365 (more) 16484002 19444077
4	MUC1	Mucin 1, Cell Surface Associated	Protein Coding	19.54	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17090193
5	KRT19	Keratin 19	Protein Coding	17.7	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19444077
6	MUC4	Mucin 4, Cell Surface Associated	Protein Coding	16.33	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17425390 17090193
7	CEACAM7	CEA Cell Adhesion Molecule 7	Protein Coding	14.67	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1700970 11006578
8	KRT5	Keratin 5	Protein Coding	14.45	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
9	NKX2-1	NK2 Homeobox 1	Protein Coding	13.35	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17036524 11224607 15084379 (more) 19444077
10	KRT8	Keratin 8	Protein Coding	12.07	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1715731 1724841
11	PDGFRA	Platelet Derived Growth Factor Receptor Alpha	Protein Coding	11.85	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
12	CEACAM5	CEA Cell Adhesion Molecule 5	Protein Coding	11.83	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	14610320
13	KDR	Kinase Insert Domain Receptor	Protein Coding	11.49	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
14	PGR	Progesterone Receptor	Protein Coding	11.41	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1774041
15	IVL	Involucrin	Protein Coding	11.14	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1737626
16	CHGA	Chromogranin A	Protein Coding	10.99	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1656682 12352185 15016319
17	PTHLH	Parathyroid Hormone Like Hormone	Protein Coding	10.84	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8107631 18836809 2348564 (more) 11506305 15864702
18	PGK1	Phosphoglycerate Kinase 1	Protein Coding	10	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
19	KRT20	Keratin 20	Protein Coding	9.92	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19859629
20	MUC5AC	Mucin 5AC, Oligomeric Mucus/Gel-Forming	Protein Coding	9.65	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17090193
21	SFTPC	Surfactant Protein C	Protein Coding	8.78	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	7671236 9020567
22	NME1	NME/NM23 Nucleoside Diphosphate Kinase 1	Protein Coding	8.19	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	7736397
23	MAPK8IP1	Mitogen-Activated Protein Kinase 8 Interacting Protein 1	Protein Coding	8.1	DISEASES inferred ¹⁴
24	FHIT	Fragile Histidine Triad Diadenosine Triphosphatase	Protein Coding	7.93	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10027335 12698186
25	SERPINA3	Serpin Family A Member 3	Protein Coding	7.44	DISEASES inferred ¹⁴ ¹⁴
26	INSM1	INSM Transcriptional Repressor 1	Protein Coding	7.34	DISEASES inferred ¹⁴
27	AR	Androgen Receptor	Protein Coding	7.33	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12558872
28	PTPRN	Protein Tyrosine Phosphatase Receptor Type N	Protein Coding	7.13	DISEASES inferred ¹⁴
29	ALK	ALK Receptor Tyrosine Kinase	Protein Coding	7.11	DISEASES inferred ¹⁴
30	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	6.97	DISEASES inferred ¹⁴
31	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	6.92	DISEASES inferred ¹⁴

Sources

Variations for Adenosquamous Carcinoma

Sources

Expression for Adenosquamous Carcinoma

Search GEO for disease gene expression data for Adenosquamous Carcinoma.

Sources

Pathways for Adenosquamous Carcinoma

Pathways related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	COPI-independent Golgi-to-ER retrograde traffic ⁶⁶ Show member pathways Cell cycle Spindle assembly and chromosome separation ²² Cytoskeleton remodeling Keratin filaments ²² Cytoskeleton remodeling Neurofilaments ²² HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand ⁶⁶	12.14	PGR KRT8 KRT7 KRT5 KRT19
2	Keratinization ⁶⁶ Show member pathways Formation of the cornified envelope ⁶⁶	11.97	KRT8 KRT7 KRT5 KRT20 KRT19 IVL
3	Cytoskeletal Signaling ³	11.59	MUC1 KRT8 KRT7 KRT5 KRT20 KRT19
4	Hippo-Merlin signaling dysregulation ⁷⁴ Show member pathways Hippo signaling regulation pathways ⁷⁴	11.54	PDGFRA KDR EGFR
5	Clear cell renal cell carcinoma pathways ⁷⁴	11.39	PGK1 PDGFRA KDR EGFR
6	Termination of O-glycan biosynthesis ⁶⁶ Show member pathways Dectin-2 family ⁶⁶ Maturation of protein 3a ⁶⁶ Maturation of protein 3a ⁶⁶	11.38	MUC5AC MUC4 MUC1
7	Vemurafenib Pathway, Pharmacodynamics ⁶⁰	11.13	PDGFRA KDR EGFR

Sources

GO Terms for Adenosquamous Carcinoma

Cellular components related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	intermediate filament	GO:0005882	9.32	KRT8 KRT7 KRT5 KRT20 KRT19

Biological processes related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	epidermis development	GO:0008544	9.73	TP63 PTHLH KRT5 EGFR
2	epithelial cell differentiation	GO:0030855	9.7	TP63 PGK1 KRT20 KRT19
3	positive regulation of phosphorylation	GO:0042327	9.62	PDGFRA KDR EGFR
4	keratinization	GO:0031424	9.56	KRT8 KRT7 KRT5 IVL
5	cell differentiation involved in embryonic placenta development	GO:0060706	9.54	KRT8 KRT19
6	intermediate filament organization	GO:0045109	9.32	KRT8 KRT7 KRT5 KRT20 KRT19

Molecular functions related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	transmembrane receptor protein tyrosine kinase activity	GO:0004714	9.73	PDGFRA KDR EGFR
2	vascular endothelial growth factor receptor activity	GO:0005021	9.46	PDGFRA KDR
3	vascular endothelial growth factor binding	GO:0038085	9.26	PDGFRA KDR
4	structural constituent of skin epidermis	GO:0030280	9.1	KRT8 KRT7 KRT5